Sat, Aug 30, 2014, 3:23 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sorrento Therapeutics, Inc. Message Board

gmeabrk 309 posts  |  Last Activity: Aug 29, 2014 10:14 AM Member since: Mar 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Ruinous Competition

    by buggyfunbunny Aug 25, 2014 11:11 AM
    gmeabrk gmeabrk Aug 29, 2014 10:14 AM Flag

    Sorry trend, but it looks to me like an offering's afoot for TROV. (Or a buyout) The stocks done great and props to Bug. This does not pose any immediate or intermediate threat to GTHP. It may end up being a complimentary technology to Luviva. I would have preferred to have heard about TROV from Bug in the high $2 range. That's what I see in GTHP. Get it when people are writing it off.

  • gmeabrk gmeabrk Aug 29, 2014 8:34 AM Flag

    Chris, now I see the premarket up this morning. My mentioning an offering is not a slam, it's just the way things are done by public companies when a product is going to take a while to gain market acceptance (read: billing code) If they don't take advantage of the stock movement to raise money I think they're crazy. While the market is still conducive to helping them,TROV would probably do better to clear the landing strip until that day . With an increase in the short interest, that's another tell. Those shorts are smart. Not perfect by any means, but smart. If your broker asks to borrow your TROV stock and pay you ridiculous interest for the privilege, either head for the hills or tag along and make money on the short side.
    One more thing, a money raise while causing dilution, could act as a poison pill and could hold a lot of potential suitors at bay because TROV is now more expensive with an as yet unapproved product. Depending on managements strategy, they may want to go it alone and this does make any acquisition more risky just by virtue of the increase money required

  • gmeabrk gmeabrk Aug 28, 2014 11:59 AM Flag

    I'm not dismissing the technology at all, it's just that I get suspicious when I see things like this. The results looked promising, but they are still going to have to buy time one way or another

  • The reason I ask is that this urine test is still a bit away from the market. The company has cash on hand, but they also have debt. They will need money to get them through the FDA if they want to get reimbursement from insurance companies. This is not meant to throw cold water on the party, I'm just asking a question. A lot of hype in a very short period always makes me curious..

  • gmeabrk gmeabrk Aug 28, 2014 11:25 AM Flag

    Being as every woman has a cervix, there's plenty of room in the pool. I still think that the profit motive of Luviva is going to be very attractive to a healthcare system that continually waits for another shoe to drop. I also have read on the TROV MB that a medical code still has yet to be issued. "No tickey, no Washey" as the old saying goes. That means that the FDA will have to initiate the same type of angst on TROV shareholders as we have suffered here at Guided . I personally think that TROV's going to announce an underwriting and take advantage of the stock movement.

  • gmeabrk gmeabrk Aug 28, 2014 9:23 AM Flag

    After trying to figure out what TROV has by way of their urine test and asking around, it is very confusing what exactly we are looking at. They speak on one hand about finding minute traces of random cancer in urine and on the other hand having specifically identified HPV. Is that from the esophagus or the cervix?
    Ironically, this urine test may actually be a boon for Guided because there's no reason to not work hand and glove with Luviva as a triage diagnostic, similar to what they are presently trying to accomplish through the FDA. All of these perceived existential threats to Guided seem to have the potential of being lifelines.

  • Reply to

    GTHP Mgmt "Executing" Shareholders at 36.5 cents

    by edfiggy Aug 27, 2014 3:47 PM
    gmeabrk gmeabrk Aug 27, 2014 5:07 PM Flag

    Hey Ed, Since Cartwright now appears to have more skin in the game than you, could you cut him a little slack? He's said straight up that he doesn't want to over dilute the stock. He's also said that he has spoken with large companies who have some interest in working with GTHP should approval happen. Knowing all that and knowing that the FDA decision gets closer with each day, could you kindly back off and see the forest through the trees. I am betting on approval and letting that lead where it leads. I have no idea where approval gets the share price, but I'll guarantee it'll be a whole lot more that .375 per share. The company will issue more shares before the approval date, but I know that Cartwright isn't interested in loading the boat prior to that approval.
    It's almost a self fulfilling prophecy regarding share price with your constant berating of management. I still have yet to understand your motivation.

  • gmeabrk gmeabrk Aug 27, 2014 4:03 PM Flag

    I'm presently waiting for the FDA approval for Luviva, the cervical diagnostic test for GTHP. The FDA has lots of questions, even for diagnostic products. The more disruptive, the more questions.
    GTHP shareholders should know by January about Luviva approval which I am predicting because no one has ever questioned the efficacy. It has been approved for use in quite a few countries including Mexico and Canada. I had occasion to speak with a very large distributor several months back and he told me that after 35 years in the medical sales business, he had never seen a new product get met with such fanfare as Luviva. That seemed good enough for me.. So you see, the FDA does approve diagnostics or not.
    Trov may take advantage of this hype and do an offering.

  • Reply to


    by scanit2008 Aug 26, 2014 5:24 PM
    gmeabrk gmeabrk Aug 27, 2014 12:12 PM Flag

    Yes, he apparently has confidence. Insiders also recently ponied up for open market shares.

  • gmeabrk gmeabrk Aug 27, 2014 10:55 AM Flag

    Wow, I'm always impressed with those that start a dialogue with Hey ignoramus. Please take note of the study that came out of the UK where Luviva diagnosed 100% of the false positive pap smears in a double blind study. Not only did they diagnose 100% of the false positives, every diagnosis that indicated that there was a problem, a problem existed.
    A light bulb? I at least gave your urinalysis it's props for maybe being a competitor. I think that when it comes down to a doctor making money on his own Luviva machine, or farming out healthcare dollars to a lab, they might opt to keep those dollars in house. The fact that the results are instantaneous, is also in the best interest of the patient.
    Are you always this strange? Just curious.

  • gmeabrk gmeabrk Aug 27, 2014 9:47 AM Flag

    Bombardment of scanners? I own GTHP and TROV was mentioned as a potential competitor. That may be the case, but the FDA will have a say in this because peoples lives are going to depend on the accuracy of the test to the FDA's satisfaction, so "wait in line"
    That being said, Luviva merely bounces harmless light off the diagnosed area which reflects off a disposable and results instantaneously appear. (I did say disposable) The Luviva test can detect precancerous cells 2 years before they manifest themselves. That allows for quicker treatment and almost 100% chance of survival.
    When you do lab work such as the TROV urine test that diagnoses on the molecular level, there will still be the human element in the handling, transport and subsequent data validation. The FDA is always curious about those things. Weird huh?

  • Reply to


    by reidosmith Aug 26, 2014 4:21 PM
    gmeabrk gmeabrk Aug 26, 2014 5:10 PM Flag

    You have gone to a lot of trouble to contribute nothing to the discussion. I owned ALQA prior to the split and have sold since. I now see where the stock gets hammered and am saying it's too cheap. Lighten up a little. Celgene seems to have a better vibe about ALQA than you and I at least know who they are. I'll again repeat, load up..

  • Reply to

    Wheres the regulars??

    by mattdagreat1 Aug 25, 2014 11:20 AM
    gmeabrk gmeabrk Aug 26, 2014 11:27 AM Flag

    For what it's worth. I think it's time to double down on ALQA. The only setback that I didn't foresee was the need for training and product education. Celgene still seems to like the partnership, and with the encouraging words from Johnson about ramping up sales of Biovance , this is going to be a winner.
    They are also talking about Big Pharma boosting their portfolios through acquisition. There's no reason to think that ALQA isn't on Celgenes radar. Never happens as quick as one likes, but I did own presplit and my sentimentality has biased my opinion.

  • gmeabrk gmeabrk Aug 26, 2014 10:59 AM Flag

    Trend, there's no question that there have been missteps with Guided,. Since I am not endowed with a female gene, I'm into forgiving the past. That doesn't mean however that I blindly forget about it.
    I come from the school that believes that Cartwright has done what's needed to be done over his short tenure. The first round of financing, though toxic, did free up GTHP to focus on results like the ones we've seen over the past several months. All these victories, whether it be the increase in sales numbers, Canada, Turkey, Mexico, Bangladesh or the trials that were conducted by the UK and now the ones in Peru and UG will all help to bolster Guided as we get nearer to the FDA decision.
    I can respect the autonomy that the FDA self imposes. With all the catalysts over the past year and the personal money invested in Guided in either loans or the buying of common stock by insiders, I am beginning to believe more and more that approval will happen. If it does, Guided will find itself in a rather enviable position where they have an approved product that utilizes a different type of technology. Cartwright from his own CC statements believes that the stock is way undervalued and he does respect the notion of not overly diluting the stock at undervalued prices if they don't have to.
    Though still a binary event in a lot of peoples minds, if FDA approval does happen, people will have to take GTHP a lot more seriously. I believe that GTHP sees a lot of value in forgoing a large money raise until the FDA decision. I believe that the company is worth at a minimum 100 million valuation should approval happen. That does make subsequent money raises a lot more palatable for us diehards.
    It's not even exclusively about Luviva being approved, but biophotonics as accepted science and GTHP's IP now having a lot more value. Intangible or not......

  • Aside from the instant results that Luviva provide, before everybody gets their panties in a bunch, why would a women's health practice give up an opportunity to make money with the introduction of Luviva to their practice? I'm not even speaking to any differences in the two tests. This is just about human nature and letting a doctor have a more "hands on" patient/doctor experience. Not to mention that with Luviva, it's more likely that a woman will get quicker treatment because results are instantaneous and a woman isn't given the opportunity of having to contact the doctors office days after the initial office visit shopuld problems be identified.
    Pap smears are not presently a profit generator for anyone involved in that pipeline. Luviva finally provides an opportunity for a practice to keep healthcare spending in their practice. That may not seem like much, but this urine test once again allows labs to get rich at the expense of a doctors individual patients. With an ever increasing environment where we will ultimately have to have death panels because the money's just not there, having something in house that allows doctors to make extra money for that car payment, should not be overlooked.

  • The point is that the company hasn't sat motionless awaiting the FDA. This is a funky month if you're trying to be an up and comer, and now with what should be a lost week with the holiday, everyone is probably better off keeping their powder dry.
    If someone gets antsy about what happened this past week, that's up to them. Too often I have sold shares in the past at the lows, only to find the stock go parabolic a short time later.. If the insiders are going to pony up on shares the day the stock tanks, they must know that whatever caused that stock to plummet was completely out of left field and they saw a steal.

  • Reply to

    Bangladesh Order

    by edfiggy Aug 21, 2014 11:22 AM
    gmeabrk gmeabrk Aug 21, 2014 12:29 PM Flag

    First off, 60 units runs 840k. (14k per Luviva machine) The distributor that wants to invest is from Turkey. Bangladesh will use more disposables per machine since their desire is for Luviva to be used as a first run diagnostic test. 60 times anything is going to be a lot of money for disposables..

  • Reply to

    Never hurts to continue the validation of Luviva.

    by gmeabrk Aug 19, 2014 9:23 AM
    gmeabrk gmeabrk Aug 19, 2014 1:41 PM Flag

    I'll still have a boatload of detractors. You can't please them all.

  • Reply to

    Never hurts to continue the validation of Luviva.

    by gmeabrk Aug 19, 2014 9:23 AM
    gmeabrk gmeabrk Aug 19, 2014 10:39 AM Flag

    There is something Star Trekkian about Luviva isn't there? I'm not going to be that big of a cynic about the FDA. Luviva is a pretty disruptive product and I know when they say disruptive, they mean that some toes are about to get stepped on.
    Pap smears are not a big income generator at $28 on average per. There is however a certain amount of cash flow that it has provided for a long time to a lot of entities in the pap smear pipe line. As for those real hard nosed turf defenders, how about those gynocologists that will hate the fact that they won't be getting additional Colposcopy income from those unnecessary Colposcopies? I hope that they are few in number, but I will guarantee that they are out there. I've known too many doctors.

  • The company keeps plodding along doing a lot more than anyone expected. We now await an FDA decision and I'm glad that Cartwright isn't hiding in a corner biting his nails awaiting their decision. These trials take less time than the 180 day window that the FDA has to respond to GTHP's refiling. It might be interesting to get further validation for Luviva in the meantime since Cartwright seems to be undaunted.
    As far as yesterdays sell off. I saw that as a ridiculous opportunity. Luviva has never been rejected by any panel, health ministry or any other entity aside from the FDA. If the FDA wants women to continue to experience the anxiety brought upon by the need for a biopsy where 40% of those are completely unnecessary, that's their call. As for me, I can just imagine the viral campaign that could be waged should the FDA in their infinite wisdom, deny Luviva for use as a triage device to screen out those who would have unnecessarily gone through a traumatic and painful ordeal.
    There's something about women's health issue that strike a nerve with the public and cervical cancer should be no exception. Being a man, I have no idea what it's like to have a Colposcpy, but I know what it's like to live with someone who has had a Colposcopy that turned out to be false positive. It's traumatic for the woman because she immediately thinks cancer when they ask her to go for a biopsy and the time that elapses between results only deepens that anxiety. The relief she felt in knowing she was alright paled in comparison to the anguish she felt in having to go through that needless process in the first place.

    Sentiment: Strong Buy

5.50+0.05(+0.92%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.